

Michele Cea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3128311/publications.pdf>

Version: 2024-02-01

129
papers

4,077
citations

147726

31
h-index

128225

60
g-index

130
all docs

130
docs citations

130
times ranked

6310
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel anti- μ B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , 2014, 123, 3128-3138.	0.6	361
2	CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. <i>Leukemia</i> , 2014, 28, 155-165.	3.3	250
3	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. <i>Blood</i> , 2016, 127, 3225-3236.	0.6	244
4	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , 2020, 583, 620-624.	13.7	198
5	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. <i>Blood</i> , 2012, 120, 1877-1887.	0.6	162
6	The NAD ⁺ -dependent Histone Deacetylase SIRT6 Promotes Cytokine Production and Migration in Pancreatic Cancer Cells by Regulating Ca ²⁺ Responses. <i>Journal of Biological Chemistry</i> , 2012, 287, 40924-40937.	1.6	151
7	Catastrophic NAD ⁺ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. <i>PLoS ONE</i> , 2009, 4, e7897.	1.1	143
8	Targeting NAD ⁺ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. <i>Blood</i> , 2012, 120, 3519-3529.	0.6	133
9	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. <i>Cell Reports</i> , 2015, 12, 622-635.	2.9	123
10	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1705-1720.	5.1	120
11	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016, 127, 1138-1150.	0.6	89
12	The KDM3A- μ KLF2- μ IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016, 7, 10258.	5.8	87
13	Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair. <i>Cancer Research</i> , 2017, 77, 3857-3869.	0.4	81
14	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. <i>Leukemia</i> , 2020, 34, 234-244.	3.3	80
15	Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. , 2017, 7, 603-621.		78
16	Intracellular NAD ⁺ depletion enhances bortezomib-induced anti-myeloma activity. <i>Blood</i> , 2013, 122, 1243-1255.	0.6	74
17	The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells. <i>Journal of Immunology</i> , 2014, 192, 1231-1240.	0.4	72
18	Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells. <i>PLoS ONE</i> , 2011, 6, e22739.	1.1	68

#	ARTICLE	IF	CITATIONS
19	Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. <i>Oncotarget</i> , 2015, 6, 11820-11832.	0.8	67
20	Nutrients in the Prevention of Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-20.	1.9	66
21	Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity. <i>Journal of Biological Chemistry</i> , 2014, 289, 34189-34204.	1.6	64
22	Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model. <i>FASEB Journal</i> , 2017, 31, 3138-3149.	0.2	62
23	Autophagy in blood cancers: biological role and therapeutic implications. <i>Haematologica</i> , 2013, 98, 1335-1343.	1.7	54
24	Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. <i>Experimental Hematology</i> , 2010, 38, 979-988.	0.2	48
25	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents. <i>Haematologica</i> , 2018, 103, 80-90.	1.7	48
26	SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells. <i>FASEB Journal</i> , 2019, 33, 3704-3717.	0.2	48
27	Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience. <i>Current Drug Targets</i> , 2013, 14, 637-643.	1.0	48
28	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 734-744.	0.9	38
29	Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. <i>Leukemia Research</i> , 2014, 38, 649-659.	0.4	38
30	SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5849-5858.	1.4	37
31	Grb7 Upregulation Is a Molecular Adaptation to HER2 Signaling Inhibition Due to Removal of Akt-Mediated Gene Repression. <i>PLoS ONE</i> , 2010, 5, e9024.	1.1	35
32	Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. <i>Blood</i> , 2017, 129, 2233-2245.	0.6	33
33	Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1295-1306.	1.2	32
34	Intracellular NAD ⁺ depletion induces autophagic death in multiple myeloma cells. <i>Autophagy</i> , 2013, 9, 410-412.	4.3	31
35	APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. <i>Clinical Cancer Research</i> , 2015, 21, 3934-3945.	3.2	31
36	Safety and Feasibility of Fasting-Mimicking Diet and Effects on Nutritional Status and Circulating Metabolic and Inflammatory Factors in Cancer Patients Undergoing Active Treatment. <i>Cancers</i> , 2021, 13, 4013.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: Added value of a Radiomics approach. <i>European Journal of Radiology</i> , 2019, 121, 108739.	1.2	28
38	Sirt6 regulates dendritic cell differentiation, maturation, and function. <i>Aging</i> , 2016, 8, 34-47.	1.4	28
39	Potent Synergistic Activity of the NAD ⁺ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 2733-2733.	0.6	28
40	Nicotinamide Phosphoribosyltransferase as a Target in Inflammation- Related Disorders. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 2930-2938.	1.0	27
41	Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition. <i>Current Cancer Drug Targets</i> , 2010, 10, 168-175.	0.8	26
42	SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice. <i>Cancer & Metabolism</i> , 2021, 9, 6.	2.4	25
43	APO866 activity in hematologic malignancies: a preclinical in vitro study. <i>Blood</i> , 2009, 113, 6035-6037.	0.6	24
44	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as Î±-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 3320-3334.	1.4	24
45	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. <i>Cancers</i> , 2020, 12, 320.	1.7	24
46	Targeting Inflammation in Primary Cardiovascular Prevention. <i>Current Pharmaceutical Design</i> , 2016, 22, 5662-5675.	0.9	23
47	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 734-44.	0.9	23
48	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2021, 39, 41-50.	0.8	22
49	Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-14.	3.3	20
50	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. <i>Clinical Cancer Research</i> , 2016, 22, 6099-6109.	3.2	19
51	Amino acid depletion triggered by Î³-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. <i>Blood Advances</i> , 2020, 4, 4312-4326.	2.5	19
52	Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8. <i>Oncotarget</i> , 2018, 9, 35056-35068.	0.8	19
53	Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent. <i>Oncotarget</i> , 2019, 10, 6723-6738.	0.8	19
54	Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-10.	1.4	17

#	ARTICLE	IF	CITATIONS
55	The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells. <i>Cancers</i> , 2019, 11, 1586.	1.7	17
56	A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. <i>Leukemia Research</i> , 2010, 34, e240-e242.	0.4	15
57	Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology. <i>Current Cancer Drug Targets</i> , 2013, 13, 779-790.	0.8	15
58	Treatment with KLEPTOSEÂ® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. <i>Vascular Pharmacology</i> , 2015, 72, 197-208.	1.0	14
59	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 7720-7727.	1.4	13
60	EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. <i>BMC Cancer</i> , 2015, 15, 855.	1.1	13
61	Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	13
62	Validation of the photography method for nutritional intake assessment in hospitalized elderly subjects. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 614-621.	1.5	13
63	Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (<sc>FLAI</sc>) provides the most useful prognostic information. <i>British Journal of Haematology</i> , 2019, 184, 457-460.	1.2	13
64	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. <i>Haematologica</i> , 2020, 105, 2420-2431.	1.7	12
65	Peripheral blood <i>vs.</i> bone marrow for molecular monitoring of BCR&AABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. <i>International Journal of Laboratory Hematology</i> , 2010, 32, 387-391.	0.7	11
66	Synthesis and cancer growth inhibitory activities of 2-fatty-alkylated pyrrolidine-3,4-diol derivatives. <i>Arkivoc</i> , 2014, 2014, 197-214.	0.3	11
67	New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy. <i>Current Cancer Drug Targets</i> , 2013, 13, 711-723.	0.8	10
68	Evaluation of prognostic indices in elderly hospitalized patients. <i>Geriatrics and Gerontology International</i> , 2017, 17, 1015-1021.	0.7	10
69	Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data. <i>Diagnostics</i> , 2021, 11, 1759.	1.3	10
70	Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor. <i>Blood</i> , 2013, 122, 124-124.	0.6	10
71	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. <i>Cancers</i> , 2021, 13, 34.	1.7	10
72	Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery. <i>Pharmaceuticals</i> , 2022, 15, 848.	1.7	10

#	ARTICLE	IF	CITATIONS
73	Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with <i>NPM1</i> mutation: from definition of molecular relapse to MRD-driven salvage approach. <i>British Journal of Haematology</i> , 2019, 186, e223-e225.	1.2	9
74	Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. <i>Leukemia and Lymphoma</i> , 2013, 54, 342-352.	0.6	8
75	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 86, 106223.	0.4	7
76	Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 84-90.	0.6	7
77	Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 107, 573-582.	1.1	7
78	Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial. <i>Blood</i> , 2020, 136, 44-45.	0.6	7
79	Effect of Geriatric Comanagement in Older Patients Undergoing Surgery for Gastrointestinal Cancer: A Retrospective, Before-and-After Study. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1868.e9-1868.e16.	1.2	7
80	Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 457-478.	2.6	6
81	Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment. <i>Haematologica</i> , 2022, 107, 1410-1426.	1.7	6
82	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	2.8	5
83	Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114504.	2.6	5
84	Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5353-5356.	1.0	4
85	Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1695-1701.	0.6	4
86	Biological Insights into Myeloma and Other B Cell Malignancies. <i>BioMed Research International</i> , 2016, 2016, 1-3.	0.9	3
87	Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 605-605.	0.6	3
88	Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. <i>Blood</i> , 2012, 120, 2932-2932.	0.6	3
89	Synthesis of Pyrrolidine 3,4-Diol Derivatives with Anticancer Activity on Pancreatic Tumor Cells. <i>Heterocycles</i> , 2014, 88, 1445.	0.4	3
90	Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells. <i>Frontiers in Immunology</i> , 2021, 12, 753890.	2.2	3

#	ARTICLE	IF	CITATIONS
91	Radiomics and artificial intelligence analysis of CT data for the identification of prognostic features in multiple myeloma. , 2020, , .		2
92	Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma. Blood, 2011, 118, 2913-2913.	0.6	2
93	Potential of crizotinib activity by fasting cycles in an ALK+ lung cancer model.. Journal of Clinical Oncology, 2014, 32, e13511-e13511.	0.8	2
94	Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study. Leukemia and Lymphoma, 2021, 62, 1897-1906.	0.6	1
95	A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML. Blood, 2018, 132, 5243-5243.	0.6	1
96	Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation. Blood, 2020, 136, 32-33.	0.6	1
97	Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment.. Blood, 2010, 116, 1215-1215.	0.6	1
98	A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia. Blood, 2015, 126, 1375-1375.	0.6	1
99	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. Current Pharmaceutical Design, 2012, 19, 734-744.	0.9	1
100	CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis. Blood, 2012, 120, 326-326.	0.6	1
101	Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing. Blood, 2013, 122, 877-877.	0.6	1
102	Editorial (Thematic Issue: Chronic Myeloid Leukemia: Reaching For the Cure). Current Cancer Drug Targets, 2013, 13, 709-710.	0.8	0
103	Exploiting tumor vulnerabilities: NAD ⁺ -depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. Expert Review of Anticancer Therapy, 2016, 16, 897-898.	1.1	0
104	Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.. Blood, 2009, 114, 4404-4404.	0.6	0
105	Catastrophic NAD ⁺ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.. Blood, 2009, 114, 4732-4732.	0.6	0
106	How Much Skin in the Game?. Journal of Structured Finance, 2011, 17, 54-58.	0.1	0
107	Targeting NAD ⁺ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells. Blood, 2011, 118, 2920-2920.	0.6	0
108	Abstract 2934: Targeting Bruton's tyrosine kinase with PCI-32765 blocks growth and survival of multiple myeloma and Waldenström macroglobulinemia via potent inhibition of osteoclastogenesis, cytokines/chemokine secretion, and myeloma stem-like cells in the bone marrow microenvironment. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
109	Compromised Nuclear Sirtuins Activity Sensitizes BRCA-Proficient multiple Myeloma Cells to DNA Damage Agents. <i>Blood</i> , 2012, 120, 723-723.	0.6	0
110	Intracellular NAD ⁺ Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity. <i>Blood</i> , 2012, 120, 330-330.	0.6	0
111	Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience. <i>Current Drug Targets</i> , 2013, 999, 1-6.	1.0	0
112	Role Of Sirtuin-6 In Maintenance Of Genomic Instability In Multiple Myeloma Cells. <i>Blood</i> , 2013, 122, 276-276.	0.6	0
113	Constitutive B-Cell Maturation Antigen (BCMA) Activation In Human Multiple Myeloma Cells Promotes Myeloma Cell Growth and Survival In The Bone Marrow Microenvironment Via Upregulated MCL-1 and NF κ B Signaling. <i>Blood</i> , 2013, 122, 681-681.	0.6	0
114	Identification Of Novel Alternative Splice Variants Of Sirtuins In Multiple Myeloma: Therapeutic Implications. <i>Blood</i> , 2013, 122, 3121-3121.	0.6	0
115	Abstract 972: B-cell maturation antigen (BCMA) activation in human multiple myeloma cells promotes myeloma cell growth and survival in the bone marrow microenvironment via upregulated MCL-1 and NF κ B signaling. , 2014, , .		0
116	Abstract 644: Novel anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity via enhanced effector function and direct tumor cell killing. , 2014, , .		0
117	A Novel Anti-a Proliferation-Inducing Ligand Hapril.01A Monoclonal Antibody Targets Multiple Myeloma Cells in the Bone Marrow Microenvironment. <i>Blood</i> , 2014, 124, 2098-2098.	0.6	0
118	The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival. <i>Blood</i> , 2015, 126, 3633-3633.	0.6	0
119	Abstract 3283: APRIL/BCMA activation promotes human multiple myeloma progression and further induces immunosuppressive bone marrow microenvironment. , 2016, , .		0
120	SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5222-5222.	0.6	0
121	CD38 Deregulation As Strategy to Make Multiple Myeloma Cells More Sensitive to NAD ⁺ Depleting Agents. <i>Blood</i> , 2016, 128, 5671-5671.	0.6	0
122	Abstract 793: The novel Bruton's tyrosine kinase inhibitor ARQ531 disrupts survival signaling and triggers apoptosis in AML cells. , 2018, , .		0
123	Abstract 4461: Sirt6 deletion slows mouse mammary tumorigenesis. , 2018, , .		0
124	Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 1585-1585.	0.6	0
125	Erwinia Chrysantemi-Derived L-Asparaginase Strongly Enhances Proteasome Inhibitors Activity By Deregulating Cell Metabolic Programs. <i>Blood</i> , 2018, 132, 3221-3221.	0.6	0
126	Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study. <i>Blood</i> , 2019, 134, 3195-3195.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespective of FLT3-ITD Allelic Burden. Blood, 2019, 134, 3828-3828.	0.6	0
128	Abstract CT075: Fasting-mimicking diet and hormone therapy modulates metabolic factors to promote breast cancer regression and reduce side effects. , 2020, , .		0
129	Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial. Blood, 2020, 136, 27-28.	0.6	0